Skip to main content

Table 2 Baseline patient characteristics

From: A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Patient characteristics

n (%)

Age

 Median (years)

61

 Range (years)

29–82

Sex

 male/female

15 (63) / 9 (38)

Disease

 ALL

11 (46)

 BCP-ALL

10

 T-ALL

1

 AML

12 (50)

 CML-BP

1 (4)

 Extramedullary disease

5 (21)

 SCT prior to study therapy

16 (67)

 SCT in AML patients

6

 SCT in ALL patients

9

 SCT in CML-BP patient

1

  1. Baseline patient characteristics reveal a median age of 61 and mainly patients with BCP-ALL and AML, who previously in most cases underwent an allogeneic SCT